About DEINOVE

Company Description

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.

The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.

Year founded

2006

Served area

Worldwide

Headcount

50

Headquarters

Cap Sigma, ZAC Euromédecine II 1682 Rue de la Valsière, 34790 Grabels – France

Shareholder information

Shares outstanding

29,110,552

IPO

April 21, 2010

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.